Thor Halfdanarson: To image or not while on PRRT…

Thor Halfdanarson, Vice President at the North American Neuroendocrine Tumor Society, shared a post on X about a recent paper by Christoph Wetz et al. published in Ovid.

“To Perform, or Not to Perform Interim PET: Questioning the Impact of Midtherapy Evaluation During PRRT in GEP-NET Patients”

Authors: Christoph Wetz, Tristan Ruhwedel, Julian Rogasch, Peter Steinhagen, Felix Bolduan, Holger Amthauer, Imke Schatka.

“To image or not while on PRRT…? According to this retrospective study of 119 pts, 30% stopped PRRT after 2 cycles for progression. This seems much higher than others have reported/experienced. We do midpoint CT or MRI before cycle 2 and many others do.

In our experience, midpoint imaging has not been very informative and infrequently changes management. That said, are there any other malignancies where you start a new therapy for progressive disease and do not scan for 10-12 months…?”

Read further.

More posts featuring Thor Halfdanarson.